
WASHINGTON, DC-Recombinant human erythropoietin is accepted treatment for chemotherapy-related anemia, but a panel of four oncology nurses convened to review an evidence-based clinical practice guideline for anemia concluded that guidelines are not being consistently followed. The panel’s findings were presented by Denise Oseguera, RN, of University of California, Los Angeles, and Susan Ross, MD, of MetaWorks Inc., Medford, Massachusetts.

